Akèy › Melanom Uveal
Etid klinik pou Melanom Uveal ap rekrite nan Etazini
22 etid pou Melanom Uveal ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Philadelphia, PA7 etid
- Los Angeles, CA6 etid
- Nashville, TN6 etid
- New York City, NY5 etid
- Boston, MA5 etid
- Columbus, OH5 etid
- Houston, TX5 etid
- Scottsdale, AZ5 etid
- Denver, CO5 etid
- Miami, FL4 etid
- Tampa, FL4 etid
- Mountain View, CA4 etid
- Aurora, CO4 etid
- Pittsburgh, PA4 etid
- Chicago, IL3 etid
- Cleveland, OH3 etid
- Madison, WI3 etid
- Durham, NC3 etid
Pa eta
- Arizona5 etid
- Colorado7 etid
- Florid8 etid
- Illinois3 etid
- Kalifòni7 etid
- Massachusetts5 etid
- Michigan3 etid
- New York7 etid
- North Carolina4 etid
- Ohio8 etid
- Pennsylvania8 etid
- Tennessee6 etid
- Texas5 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05607095Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07804186Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06070012A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 19, 2026 · NCT07636785Tebentafusp-tebn With LDT in Metastatic UM
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT06626516Adjuvant Tebentafusp in High Risk Ocular Melanoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06246149Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06961357Adjuvant Quisinostat in High-Risk Uveal Melanoma
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06932757A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Jun 15, 2026 · NCT06940739Neoadjuvant Tebentafusp for Uveal Melanoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06414590Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Apr 2, 2026 · NCT06581406Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 31, 2026 · NCT07276386Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Mar 17, 2026 · NCT04119024Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 11, 2026 · NCT07364474Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Mar 9, 2026 · NCT04792463Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT06627244Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 4, 2025 · NCT06121180Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 28, 2025 · NCT07136181A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2025 · NCT06805825Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.